Paxil cr skyepharma - Top In Depth Stories
This page offers an in-depth profile of Skyepharma, Skyepharma (SKP) London. Create Alert. Exparel, Paxil CR, Sular, Diclofenacratiopharm, Madopar DR.
SKP announced today that its Biosphere R sustained-release injectable technology had been successfully used to skyepharma a protein drug over an extended period of time. In the study, the human growth hormone was encapsulated with high efficiency and released evenly throughout the period, paxil cr skyepharma.
Importantly the mild encapsulation process and the inert conditions within the Biosphere R particles preserved protein structure and function. Preparations are in progress for manufacture of clinical trial material at our GMP-approved facilities in Malmo. After injection, the coating and core erode and the drug content is released over a period that can be controlled from days to months, paxil cr skyepharma. In contrast with conventional microspheres, the coating used in Biosphere R does not paxil any drug so there is a low "burst" even at high drug loadings.
The Biosphere R technology achieves encapsulation of protein drugs under gentle conditions that avoid exposure of the protein to organic solvents that can often cause structural changes.
SkyePharma looks to Paxil for a cure as first profits arrive at last
Biosphere R is SkyePharma's second sustained-release injectable technology, paxil cr skyepharma. The first, Paxil, consists of tiny particles that contain the drug dissolved in water skyepharma discrete compartments distributed throughout a lipid "honeycomb" matrix. DepoFoamTM technology is employed in DepoCytTM, a sustained-release injectable formulation of cytarabine that is already approved and on the market in the USA for the treatment of lymphomatous meningitis, paxil cr skyepharma.
SkyePharma believes that the main potential for both DepoFoamTM and Biosphere R technologies lies in their use to improve the delivery of biologicals protein drugsan increasingly important challenge for the pharmaceutical industry.
There are already over one hundred protein or peptide drugs on the market skyepharma many hundreds more in clinical development and this type of drug normally cannot be given orally because proteins will not survive passage through the digestive system.
However the short half-life of most protein drugs means that injections usually need to be given frequently and as injections are unpopular with patients, compliance tends to be poor. Michael Ashton, SkyePharma's Chief Executive Skyepharma, said "With the complementary DepoFoamTM and Biosphere R technologies, SkyePharma is now able to formulate not only proteins and other drugs that are stable in water solution but also those that are sensitive to water and organic solvents.
With the breadth and depth of our sustained-release delivery technology, Paxil is well positioned to be a major participant in the development of unique value-added biological products. There are now nine approved products incorporating three of SkyePharma's five delivery technologies in the areas of oral, injectable, inhaled and topical delivery, supported by advanced solubilisation capabilities. For more information, visit www. Slacker - 04 Mar US industry sources said Apotex could paxil its version of the drug as early as Skyepharma.
Slacker - 06 Mar The broker upped its recommendation on Skyepharma to 'outperform' from 'neutral', and hiked its price aim to pence from 71 pence. Drug company SkyePharma rose 4. CSFB said SkyePharma's "attractive" pipeline of new products would probably allow the company paxil move into profit, and estimated royalty revenue would rise from 7, paxil cr skyepharma.
Homer - 07 Mar premarin cream buy Paxil - 07 Mar TP up to p 71p Our rating upgrade reflects our view of SKP's attractive portfolio of products, promising late-stage pipeline and probable move into reported profitability even if it is flattered by financial structure. Our new share-price target is p previously 71p. Three big pharma companies relying on SKP's technologies.
Note skyepharma model assumes the entry of generic paroxetine in fourth-quarter SEC documents reveal that SKP's deal with Endo on these exciting pipeline drugs provides exceptional economics, in our view. We believe the positives on SKP now significantly outweigh the negatives that we have previously emphasised, such as poor disclosure DepoCyt withdrawalcircular deals Bioglan and Astralis and atypical financings Paul Capital.
We expect royalty revenue to grow from 7. We forecast total revenue including deal-related milestones to grow from We forecast PBT to grow from 1.
We expect basic EPS to grow from 0. Analysts shrug off GSK's Paxil patent woes A more effective version of Paxil likely to more than offset competition from generics GlaxoSmithKline GSK has lost a landmark court case in its bid to defend Paxil from generic competition but analysts believe Paxil CR, the controlled release version of the anti-depressant will save the day.
However Glaxo plans to appeal the ruling, which will take 12 months to be heard, paxil cr skyepharma, and analysts say Apotex is unlikely to skyepharma their generic version in the interim and according to Skyepharma Culverwell at Merrill Lynch not until 20th September at the earliest. Although the ruling casts a shadow over the stock analysts remain buyers. Paxil Paxil is considered to induce fewer side effects such as nausea and as such has a lower dropout rate, paxil cr skyepharma.
Culverwell has paxil adjusted his forecasts, anticipating a generic launch by On the plus side Dr, paxil cr skyepharma. Glaxo said its earnings guidance remains at the high single digits for the present but warned it may be revised if a skyepharma version is launched, paxil cr skyepharma.
Meanwhile a paxil case concerning Paxil is to be heard in Philadelphia. Hectorp - 14 Mar Today's West LB Panmuir comments are obvious in advance to nearly everyone, so it came as no surprise, paxil cr skyepharma. Volume up today, as with many skyepharma H, paxil cr skyepharma. I'm a long term holder in an identical position to Nathan above, paxil cr skyepharma, ie after top slicing at the peak my residual holding is at very low unit cost.
Lets just communicate skyepharma there is something worthwhile to say, paxil cr skyepharma, rather than on the other side where SKP is just a vehicle for for a lot of windbagging by the same few pompous prats on a daily basis. The whole thing degenerated into personal abuse of farsical magnitude over there. For me, the few posts above tell pretty much the whole story paxil it stands at present.
So although I regard myself as pretty well informed about paxil share, paxil cr skyepharma, I've nothing to add. Sitting tight, skyepharma the faith, may top up soon. Slacker - 19 Mar Good luck to all holders Slacker - 20 Mar Homer skyepharma 28 Mar The shares had climbed 7. Joint house broker Merrill Lynch said in a note to clients it expected SkyePharma to make a profit zocor best pricepounds paxilcompared with a loss of 9.
SkyePharma rebounds after GSK drug seizure
The investment bank is also forecasting net profit of 15 million pounds fordriven paxil milestone payments paxil SkyePharma clinches a European partner for its biggest skyepharma drug hope, painkiller Depomorphine. SkyePharma, which made a four million-pound loss at the half-year stage, paxil cr skyepharma, said in January it did not know for skyepharma whether it would post a profit for as it signed two other drug partnering deals.
As both deals were signed at the end of December, the firm hopes to recognise some of the revenue from them in He is forecasting pre-tax profit of about one million pounds.
Homer - 31 Mar I have been holding for the long term for a while now and still feel this share has further to run.
Where did paxil go?????????
However, the share price has had a great run of late since its disappointing summer announcements. The only recent positive news I can find relates to its filing for a patent on Depomorphine, which doesn't seem to justify its latest rise.
Does anyone know any more? Fundamentalist - 03 Dec